Improving T cell therapy for solid tumors by targeting specific immune cells in lymph nodes
Official title: Improving engineered TCR-T cell therapy for solid tumors by targeting Tcf1+ stem-like reservoirs in tumor-draining lymph nodes
Funded at Fred Hutchinson Cancer Center · NIH-10997222 · Data updated 2026-11-12
This study is looking at how to make special immune cells called T cells better at fighting solid tumors by learning from a type of T cell found in lymph nodes, which could help improve cancer treatments for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 16, 2024 |
| Project end | August 15, 2026 |
| Funding year | 2024 |
| Award (this year) | $44,154 |
| NIH project number | 1F31CA294918-01 |
| Project ID | NIH-10997222 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors who are considering or currently undergoing T cell therapy.
✕Less likely to help
Patients with hematological malignancies or those who do not have solid tumors may not benefit from this research.
What this research studies
This research investigates how engineered T cells can be improved for treating solid tumors by focusing on a specific type of immune cell found in tumor-draining lymph nodes. The study aims to understand the characteristics of these stem-like T cells, which can self-renew and become effective against tumors. By comparing these cells with engineered T cells, the research seeks to identify ways to enhance the persistence and functionality of T cell therapies. Patients may benefit from insights that could lead to more effective cancer treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective T cell therapies for patients with solid tumors, improving treatment outcomes.
How similar studies have gone: Other research has shown promise in enhancing T cell therapies by targeting specific immune cell populations, indicating potential for success in this approach.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Nutt, William Samuel — Fred Hutchinson Cancer Center
- Study coordinator: Nutt, William Samuel
Related research
Other NIH-funded projects on the same topics.
-
Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors
A program uses mouse tumor models to identify promising drug candidates for children with sarcoma and other solid tumors.
-
Engineered CAR T immune cells targeting GPC3 for children's solid tumors
Engineered CAR T immune cells that produce IL-15 and IL-21 to better find and fight GPC3-positive solid tumors in children.
-
Boosting CAR T cell power in solid tumors by turning on transcription factors
A new research project tests whether turning on specific human transcription factors can make CAR T cells work better against solid tumors.
-
Engineering CD19 mimotopes to boost and broaden CD19-CAR T cell therapy
A patient-focused look at improving existing CD19-CAR T cell therapy so more people with blood cancers might benefit.
-
Radio-triggered CAR-T cells to better control solid tumors
A new approach uses radiation to turn on and guide CAR-T cells to fight solid tumors more effectively, potentially improving local and distant tumor control for patients with cancer.
-
Understanding how cell behavior changes drive breast cancer in 3D cultures
Researchers are studying how breast cells transition toward cancer using advanced 3D cultures and patient-derived samples to uncover important cell-state changes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.